argx-119
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 21, 2023 (NCT05670704)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068571 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07287982 | Phase 2 | Dec 19, 2025 | argenx |
| NCT06441682 | Phase 2 | Oct 23, 2024 | argenx |
| NCT06436742 | Phase 1 | Sep 24, 2024 | argenx |
| NCT05670704 | Phase 1 | Feb 21, 2023 | argenx |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| argenx | For profit | 4 | 4 | 2 | 2023 |
1 organizations
Page 1 / 1